Professor, Oncology, Mayo Medical School
Radiation Oncology
Dr. Jann N. Sarkaria, MD
|
|
Give Review
Jann N. Sarkaria practices Radiation Oncology. He researched medicine at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is one of the top medical schools in the US. David Geffen School of Medicine at UCLA is ranked 13/7 in Research/PrimaryCare. Jann N. Sarkaria, MD is also a published physician. He has 62 publication published. The most recent publication is: Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins. Jann N. Sarkaria, MD is registered with Medicare and accepts Medicare payments.
Publications
- Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.
- Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for O...
- CNS AntiCancer Drug Discovery and Development Conference White Paper.
- Src family kinases differentially influence glioma growth and motility.
- Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tum...
- Improving drug delivery to primary and metastatic Brain tumors: Strategies to overcome the blood-Brain barrier.
- The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
- NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification.
- Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group.
- Design and characterization of an economical (192)Ir hemi-Brain small animal irradiator.
- Factors Influencing the CNS Distribution of a Novel MEK 1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases.
- EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.
- A novel synthetic 1,3-phenyl bis-urea compound targets microtubule polymerization to cause Cancer cell death.
- Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory m...
- Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells.
- Increased Bowel Toxicity in Patients Treated With a Vascular Endothelial Growth Factor Inhibitor (VEGFI) After Stereotactic Body Radiation Therapy (SBRT).
- Biopsy validation of 18F-DOPA PET and biodistribution in Gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study.
- Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
- Targeting SRC family kinases inhibits bevacizumab-induced glioma cell invasion.
- Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
- Impairment of glioma stem cell survival and growth by a novel inhibitor for survivin-ran protein complex.
- The role of LAT1 in (18)F-DOPA uptake in malignant Gliomas.
- Active efflux of dasatinib from the Brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly-targeted agents.
- Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts.
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
- Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
- Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFR?-stimulated glioma tumorigenesis in mice and humans.
- Establishment, Maintenance and in vitro and in vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and ...
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.
- A phase 2 study of temsirolimus (CCI-779) in patients with Soft tissue sarcomas: A study of the mayo phase 2 consortium (P2C).
- Acquisition of temozolomide chemoresistance in Gliomas leads to remodeling of mitochondrial electron transport chain.
- Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious ...
- Expression of CD74 in high grade Gliomas: a potential role in temozolomide resistance.
- North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Patients with Newly Diagnosed...
- ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of Gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the b...
- Phenotypic variations in NF1-associated low grade Astrocytomas: possible role for increased mTOR activation in a subset.
- Misregulated E-cadherin expression associated with an aggressive Brain tumor phenotype.
- Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
- Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
- Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
- Bioluminescent imaging of intracranial vestibular Schwannoma xenografts in NOD/SCID mice.
- p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
- Gene expression profiling of NF-1-associated and sporadic pilocytic Astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed can...
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group...
- PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel.
- Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
- Mechanisms of chemoresistance to alkylating agents in Malignant glioma.
- Overview of Cancer molecular radiobiology.
- Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
- Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
- Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung Cancer.
- Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
- Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
- Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
- Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.
- Identifying inhibitors of ATM and ATR kinase activities.
- Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant Gliomas.
- Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.
- Peptide Carrier-Mediated Non-Covalent Delivery of Unmodified Cisplatin, Methotrexate and Other Agents via Intravenous Route to the Brain.
- MARQUIS: a multiplex method for absolute quantification of peptides and posttranslational modifications.
Schools
University Of California Los Angeles School Of Medicine
University Hi J a Burns School Med
University Of Wi Hospital and Cli
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Oncology
- Radiation Oncology
Accepted Insurances
Education
-
University of Wisconsin -
University of Hawaii -
David Geffen School of Medicine at UCLA
Hospital
-
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225018419 |
| Last Name Of The Provider | SARKARIA |
| First Name Of The Provider | JANN |
| View All |
Similar Doctors
|
|
Dr. Scott L. Stafford, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kiernan J. Minehan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Ma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth R. Olivier, MD |
|
|
Dr. David J. Schwartz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna J. Springer, MD |
|
|
Dr. Stephanie K. Childs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul D. Brown, MD |
|
|
Dr. Lindsay C. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miran J. Blanchard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fawaad O. Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shakila P. Khan, MD |
|
|
Dr. Benjamin Mou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bradley J. Stish, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ron S. Smith, MD
This Doctor is OpenDoctor Recommended.
|